Bedrijfsvoering The Medicines Company

MDCO

US5846881051

Farmaceutische producten

Vertraagde tijd Nasdaq Andere beurzen			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
- ^USD	-.--%		+0,14%	-0,05%

25/11	Novartis AG, The Medicines Company - M&A Call
18/11	The Medicines Company - Special Call

Uitvoerend comité: The Medicines Company

Bedrijfsleider

Beklede functiesVan

Stephen M. Rodin

48 jaar

General Counsel	-
Corporate Officer/Principal	-

Krishna Gorti

Investor Relations Contact

Samenstelling van de raad van bestuur: The Medicines Company

Directeur

RadenVan

John C. Kelly

82 jaar

Audit Committee Chair

29-04-2011

Voormalige zaakvoerders en bestuurders: The Medicines Company

Insider

Beklede functies

VanTot

Clive Meanwell

Director/Board Member	01-08-2004	06-01-2020
Chief Executive Officer	01-08-2004	-
Chairman	25-09-2001	01-08-2004
Founder	31-07-1996	06-01-2020
President	01-10-2009	01-12-2012

William W. Crouse

Director/Board Member	01-04-2003	31-05-2018
Independent Dir/Board Member	01-04-2003	31-05-2018

Bill O'Connor

Comptroller/Controller/Auditor	23-07-2009	-
Director of Finance/CFO	01-01-2016	27-03-2018

Jeffrey A. Frazier

Corporate Officer/Principal

01-06-2014

19-03-2018

Robert Hugin

Director/Board Member	01-04-2003	05-02-2018
Independent Dir/Board Member	15-11-2011	05-02-2018

Melvin Spigelman

Director/Board Member	27-09-2005	01-01-2018
Independent Dir/Board Member	27-09-2005	01-01-2018

Gregory Moeck

Corporate Officer/Principal

01-12-2017

Tanya Quinn

Corporate Officer/Principal

01-11-2016

Robert G. Savage

Director/Board Member	01-04-2003	14-08-2016
Independent Dir/Board Member	01-04-2003	14-08-2016

Bob Laverty

Public Communications Contact

01-07-2016

Glenn Sblendorio

Director/Board Member	01-07-2000	01-03-2016
Director of Finance/CFO	03-03-2006	01-03-2016
Independent Dir/Board Member	01-07-2000	23-11-2011
President	19-04-2012	01-03-2016
Treasurer	23-07-2009	01-03-2016

Neera D. Ravindran

Public Communications Contact	-	01-10-2015
Corporate Officer/Principal	-	12-03-2015

Rob Mitchell

Corporate Officer/Principal

01-01-2011

01-08-2015

Adam Sharkawy

Corporate Officer/Principal

01-01-2015

Matthew Wikler

Corporate Officer/Principal

01-01-2012

01-01-2015

Paul Antinori

General Counsel	01-05-2002	03-03-2014
Corporate Secretary	01-05-2002	03-03-2014

Brent Furse

Corporate Officer/Principal

01-06-2000

01-01-2014

Sanuj K. Ravindran

Corporate Officer/Principal

18-09-2012

Cornelis J. Heiman

Corporate Officer/Principal

19-06-2012

Leslie C. Rohrbacker

Corporate Officer/Principal

12-05-2010

16-04-2012

Gregory Fiore

Chief Tech/Sci/R&D Officer

01-01-2012

James Ferguson

Corporate Officer/Principal

01-01-2008

01-05-2010

John Kelley

Chief Operating Officer	01-12-2004	01-10-2009
President	01-12-2004	01-10-2009

Catharine S. Newberry

Human Resources Officer

01-02-2006

26-01-2009

Kelli Watson-Pacicco

Corporate Officer/Principal

23-07-2009

Brian Leuthner

Sales & Marketing

01-01-2005

01-01-2007

Hiroaki Shigeta

Director/Board Member	09-04-2007	-
Independent Dir/Board Member	09-04-2007	-

Steven Hubrig Koehler

Director of Finance/CFO	01-03-2002	17-03-2006
Treasurer	01-03-2002	17-03-2006

Dennis P. Reilly

Comptroller/Controller/Auditor	01-05-2002	01-09-2005
Director/Board Member	01-05-2002	01-09-2005

Leonard Bell

Director/Board Member

01-05-2000

01-04-2005

Elizabeth Hamilton Seabury Wyatt

Director/Board Member	01-03-2005	-
Independent Dir/Board Member	01-03-2005	-

James Edward Thomas

Director/Board Member

01-09-1996

01-02-2005

Ali Behbahani

Consultant / Advisor

01-01-2003

01-01-2005

Fred M. Ryan

Director/Board Member	01-01-2005	01-01-2005
Corporate Officer/Principal	01-01-2005	01-01-2005

David Stack

Director/Board Member	25-09-2001	01-08-2004
Chief Executive Officer	25-09-2001	01-08-2004
President	25-09-2001	01-08-2004

Fazle Husain

Director/Board Member

01-09-1998

01-10-2003

Anthony Flammia

Corporate Officer/Principal

01-06-2003

Robert B. Pelletier

Director of Finance/CFO

01-07-2000

01-03-2003

Michael Mitchell

Investor Relations Contact

01-07-2002

Jennifer Foley

Chief Tech/Sci/R&D Officer

01-07-2000

01-02-2002

Peter Teuber

Corporate Officer/Principal

21-06-2001

Gary Dickinson

Human Resources Officer

01-04-2001

Thomas Lategan

General Counsel

01-03-1997

01-02-2000

Christina Willwerth

Corporate Officer/Principal

01-01-1998

01-01-2000

Armin M. Kessler

Director/Board Member	01-10-1998	-
Independent Dir/Board Member	15-11-2011	-

John Richards

Corporate Officer/Principal

01-10-1997

T. Scott Johnson

Chief Tech/Sci/R&D Officer	14-11-2011	-
Founder	01-09-1996	-
Corporate Officer/Principal	24-07-2009	14-11-2011

John W. Villiger

Founder	31-07-1996	-
Corporate Officer/Principal	31-07-1996	-

Helmut Giersiefen

Chief Tech/Sci/R&D Officer	31-07-1996	-
Founder	31-07-1996	-

Donald Haut

Corporate Officer/Principal

Richard Malcolm

Corporate Officer/Principal

David Kallend

Chief Tech/Sci/R&D Officer	04-04-2013	-
Corporate Officer/Principal	-	04-04-2013

Joanne Jones

Corporate Officer/Principal

Peyton J. Marshall

Director of Finance/CFO

Mike McGuire

Corporate Officer/Principal

01-01-2011

Clive Reading

Corporate Officer/Principal

Michelle Lockhart

Corporate Officer/Principal

James B. Jones

Corporate Officer/Principal

Ray Russo

Corporate Officer/Principal

Jill Fawdon

Public Communications Contact

29-06-2009

Sara Nochur

General Counsel

Thomas Quinn

Corporate Officer/Principal

Edwina White

Corporate Officer/Principal

Mario Azevedo

Corporate Officer/Principal

Glyn Parkin

Chief Operating Officer	-	23-07-2009
Corporate Officer/Principal	23-07-2009	-

Taunia S. Markvicka

Sales & Marketing

Robyn Brown

Public Communications Contact

23-07-2009

Nancye L. Green

Public Communications Contact

Gary C. Cupit

Corporate Officer/Principal

Bruce C. Cooper

Corporate Officer/Principal

Leeftijdsdistributie van bedrijfsleiders

Ratio vrouwen/mannen

Man	3
Vrouw	0

Waarvan leden van het uitvoerend comité

Man	2
Vrouw	0

Waarvan bestuurders

Man	1
Vrouw	0

ESG MSCI

The Medicines Company is een wereldwijd biofarmaceutisch bedrijf. Het bedrijf richt zich op de ontwikkeling van inclisiran, een tweejaarlijkse therapie die toediening mogelijk maakt tijdens routinebezoeken van patiënten aan hun zorgverleners en mogelijk bijdraagt aan een betere therapietrouw van patiënten en aanhoudend lagere LDL-C-niveaus. Het bedrijf is een dochteronderneming van Novartis AG.

Werknemers

Sector

Farmaceutische producten

Meer informatie over het bedrijf